Inclusion Criteria:

- Elderly patients 75 years old or more

- Life expectancy of greater then or equal to 6 months

- Histologically proven metastatic breast or colorectal cancer, requiring a
chemotherapy by capecitabine according to the habitual schema

- Metastatic situation whatever treatment line

- Previous hormonotherapy for breast cancer, prior chemotherapy (without capecitabine)
in adjuvant and/or metastatic indication (colorectal or breast cancer), or
radiotherapy (colorectal or breast cancer) are allowed

- One or more measurable target lesion (RECIST criteria)

- ADL>4 (geriatric scales)

- GSD<12 (geriatric scales)

- Laboratory values :

- creatinine clearance (CrCl) >=30 mL/min according to Cockcroft formula

- Adequate bone marrow function (neutrophils count > 1.5 x 10^9/L, platelets > 100
x 10^9/L, hemoglobin [Hb] > 10g/dl)

- Adequate hepatic function: total bilirubin < 1,5 x upper normal limit, aspartate
aminotransferase (ASAT) and alanine aminotransferase (ALAT) < 2,5x upper normal
limits (in case of liver metastases < 5 x upper normal limits)

- Alcalin phosphatases <=2,5x ULN (<=5 x ULN if liver metastases present).

- Subjects must be willing to be followed during the course of treatment/observation
and follow-up.

- Signed written informed consent before first course of chemotheray

Exclusion Criteria:

- Age < 75 years

- known brain metastases

- Concomitant oncologic treatment ongoing

- History of severe or unscheduled reaction to fluoropyrimidine treatment

- Prior unanticipated severe reaction to capecitabine or metabolites and to
fluoropyrimidine therapy

- Patient with leucopenia

- sorivudine or chemical analogues treatment like brivudine

- Physiological, familial, sociological, or geographical conditions that do not permit
compliance with the protocol.

- Concomitant severe affections wich lead life expectancy inferior to 3 monthes

- Uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure,
coronarian spasmes

- No possible oral administration

- known DPD deficiency

- Treatment with experimental therapy ongoing or within four weeks before inclusion.

- Other cancers within the last five years, with the exception of adequately treated
cone-biopsied in situ carcinoma of the uterin cervix or basal or squamous cell
carcinoma of the skin